Strategic Hiring Dunad Therapeutics has recently appointed a new Chief Medical Officer (Feb 2026) which signals near-term clinical development acceleration and potential demand for translational medicine collaboration, CRO alignment, and advisory services to support imminent trial planning and regulatory strategy.

Clinical Leadership A high-profile shift with a former Chief Scientific Officer departure in 2024 and new leadership in medical affairs suggests opportunities for partnerships around target validation, biomarker strategy, and proteomics-driven drug discovery support with CROs and academic collaborations.

Proteomics Focus Active participation in proteomics-based drug discovery events (Feb 2026) indicates readiness to engage with proteomics platforms, assay development partners, and mass-spectrometry service providers to bolster target engagement and discovery workflows.

Funding & Scale Revenue in the mid-range and total funding of modest scale imply room for strategic partnerships, co-development agreements, or advisory services to optimize pipelines, accelerate lead optimization, and secure additional non-dilutive or venture funding rounds.

Global Partners Industry peers listed in similar company comparisons show a landscape where Dunad could benefit from BD collaborations with biotech partners, contract research organizations, and technology providers to expand covalent chemistry capabilities, data analytics, and commercialization readiness.